Q3 EPS Estimate for Prenetics Global Decreased by Analyst

Prenetics Global Limited (NASDAQ:PRE) – Zacks Research reduced their Q3 2026 earnings estimates for Prenetics Global in a research note issued on Tuesday, August 18th. Zacks Research analyst B. Sorensen now expects that the company will earn ($0.25) per share for the quarter, down from their previous forecast of ($0.08). The consensus estimate for Prenetics Global’s current full-year earnings is ($1.28) per share. Zacks Research also issued estimates for Prenetics Global’s Q4 2026 earnings at $0.20 EPS, FY2026 earnings at ($1.14) EPS and Q1 2027 earnings at ($0.13) EPS.

PRE has been the topic of a number of other reports. Wall Street Zen lowered shares of Prenetics Global from a “hold” rating to a “sell” rating in a research note on Saturday, July 25th. Benchmark increased their price target on Prenetics Global from $30.00 to $40.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Weiss Ratings restated a “sell (d-)” rating on shares of Prenetics Global in a report on Friday, July 17th. Four research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat, Prenetics Global presently has a consensus rating of “Moderate Buy” and a consensus price target of $34.25.

Prenetics Global Price Performance

NASDAQ:PRE opened at $17.97 on Friday. Prenetics Global has a one year low of $7.18 and a one year high of $23.63. The company has a market cap of $303.15 million, a PE ratio of -4.32 and a beta of 0.26. The firm’s 50 day simple moving average is $19.08 and its 200 day simple moving average is $18.88.

Prenetics Global (NASDAQ:PRE) last released its quarterly earnings data on Wednesday, August 19th. The company reported ($0.53) earnings per share for the quarter, beating the consensus estimate of ($0.84) by $0.31. Prenetics Global had a negative return on equity of 21.41% and a negative net margin of 47.43%.The business had revenue of $46.49 million for the quarter, compared to analyst estimates of $49.85 million.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. JPMorgan Chase & Co. bought a new position in Prenetics Global in the 3rd quarter valued at $65,000. UBS Group AG raised its stake in shares of Prenetics Global by 581.9% in the third quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after buying an additional 39,733 shares during the period. Kingsview Wealth Management LLC purchased a new position in shares of Prenetics Global during the 4th quarter valued at $172,000. Goldman Sachs Group Inc. bought a new position in shares of Prenetics Global during the 4th quarter worth $665,000. Finally, T3 Companies LLC purchased a new position in shares of Prenetics Global in the fourth quarter worth about $170,000. 25.01% of the stock is currently owned by hedge funds and other institutional investors.

More Prenetics Global News

Here are the key news stories impacting Prenetics Global this week:

• Positive Sentiment: IM8 reported Q2 2026 revenue growth of 288% year over year and raised its FY 2026 revenue guidance to $220–$230 million. Prenetics also initiated FY 2027 revenue guidance of at least $400 million, signaling management expects rapid growth to continue. IM8 Q2 2026 revenue and guidance article
• Positive Sentiment: Actress and producer Lily Collins will become IM8’s first film-and-television global ambassador and a Prenetics shareholder under a multi-year partnership. Her reach of more than 33 million social-media followers is expected to broaden IM8’s exposure, particularly among female consumers, beyond its existing sports-focused ambassador roster. Lily Collins IM8 partnership article
• Positive Sentiment: Management said IM8 has delivered more than 57 million servings, ships approximately 200,000 servings daily across 46 countries, and generated 54% of revenue outside the United States. Prenetics also reported positive consolidated adjusted free cash flow in July and expects to remain positive through the third quarter and beyond.
• Neutral Sentiment: Analyst estimate changes were mixed: Sidoti modestly raised its Q1 2028 EPS forecast to $0.29 but trimmed its FY 2028 estimate to $2.12, while Zacks lowered its FY 2027 EPS estimate to $1.49 from $1.56. The revisions do not materially change the broader growth narrative.
• Negative Sentiment: The elevated 2026–2027 targets are forward-looking and depend on sustained IM8 demand, successful product launches—including hydration and gummies—and effective marketing. Prenetics remains unprofitable, with consensus estimates calling for a current-year loss of $1.28 per share, leaving execution risk significant.

About Prenetics Global

Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.

Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.